Demonstration of vitamin D3 metabolism inmytilus edulis

I. Lehtovaara,T. Koskinen

DOI: https://doi.org/10.1007/BF01952438

1986-02-01

Experientia

Abstract:

What problem does this paper attempt to address?

International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023)

Shengsheng Zhang,Luqing Zhao,Hong Shen,Zhipeng Tang,Danping Qin,Junxiang Li,Beiping Zhang,Guanhu Yang,Minhu Chen,Kaichun Wu,Zhanju Liu,Hong Yang,Huahong Wang,Ye Zong,Yaolong Chen,Shuyuan Xiao,Qiang Cai

DOI: https://doi.org/10.1002/ptr.8087

IF: 6.388

2023-12-19

Phytotherapy Research

Abstract:Abstract Ulcerative colitis (UC), a chronic and nonspecific inflammatory disease of the intestine, has become a prevalent global health concern. This guideline aims to equip clinicians and caregivers with effective strategies for the treatment and management of adult UC patients using traditional Chinese medicine (TCM). The guideline systematically evaluated contemporary evidence through the Grading of Recommendations Assessment, Development, and Evaluation framework. Additionally, it incorporated insights from ancient Chinese medical sources, employing the evidence grading method found in traditional TCM literature. The development process involved collaboration with multidisciplinary experts and included input from patients with UC. The guideline, based on a comprehensive review of available evidence, present 40 recommendations. They offer a condensed overview of TCM's role in understanding the pathogenesis, diagnosis, and treatment of UC, along with an assessment of the efficacy of various TCM‐based treatments. TCM exhibits promising outcomes in the treatment of UC. However, to establish its efficacy conclusively, further high‐quality clinical studies on TCM for UC are essential.

pharmacology & pharmacy,chemistry, medicinal
On the validity of continuous spectrophotometric assays for adenosine deaminase activity: a critical reappraisal.

G. Cercignani,S. Allegrini

DOI: https://doi.org/10.1016/0003-2697(91)90541-Z

IF: 2.9

1991-02-01

Analytical Biochemistry

Abstract:
Update of the PANCCO clinical practice guidelines for the treatment of ulcerative colitis in the adult population

F Juliao-Baños,C F Grillo-Ardila,I Alfaro,M T Andara-Ramírez,O Avelar-Escobar,J Barahona-Garrido,S Bautista-Martínez,F J Bosques-Padilla,J A De Paula,K Ernest-Suárez,M T Galiano,B Iade-Vergara,Patricio-Ibañez,M L Jara-Alba,P G Kotze,M C Miranda-Ojeda,R Ortuño-Escalante,G Otoya-Moreno,F N Piñol-Jiménez,I C Ramos-Polo,A Sambuelli,M Toro,E A Torres,G R Veitia-Velásquez,J K Yamamoto-Furusho,C Zaltman,F Steinwurz,M Vallejo-Ortega,J I Torres-Castillo,C Hamon-Pinilla,C H Calderon-Franco,A M Escobar-Villegas,Developer group

DOI: https://doi.org/10.1016/j.rgmxen.2022.04.006

Abstract:Ulcerative colitis (US) is a chronic disease of unknown etiology. It is incurable and its clinical course is intermittent, characterized by periods of remission and relapse. The prevalence and incidence of the disease has been increasing worldwide. The update presented herein includes the participation of healthcare professionals, decision-makers, and a representative of the patients, all of whom declared their conflicts of interest. Answerable clinical questions were formulated, and the outcomes were graded. The information search was conducted on the Medline/PubMed, Embase, Epistemonikos, and LILACS databases, and covered grey literature sources, as well. The search was updated on November 30, 2020, with no restrictions regarding date or language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) classification system was implemented to establish the strength of the recommendation and quality of evidence. A formal consensus was developed, based on the RAND/UCLA methodology and the document was peer reviewed. The short version of the Clinical Practice Guidelines for the Treatment of Ulcerative Colitis in the Adult Population is presented herein, together with the supporting evidence and respective recommendations. In mild-to-moderate UC, budesonide MMX is an option when treatment with 5-ASA fails, and before using systemic steroids. In moderate-to-severe UC, infliximab, adalimumab, vedolizumab, ustekinumab, and tofacitinib can be used as first-line therapy. If there is anti-TNF therapy failure, ustekinumab and tofacitinib provide the best results. In patients with antibiotic-refractory pouchitis, anti-TNFs are the treatment of choice.
Expert consensus on diagnosis and treatment of ulcerative colitis with integrated traditional Chinese and Western medicine: A nursing perspective

Bing Xu,Miao Liu,Hairong Hu,Jing Zhang,Yanping Huang,Ling Tang

DOI: https://doi.org/10.4103/jin.jin_22_22

2023-03-23

Journal of Integrative Nursing

Abstract:Ulcerative colitis (UC) is a chronic nonspecific intestinal inflammatory disease of unclear etiology, characterized by continuous and diffuse inflammatory changes of colorectal mucosa. In recent years, the incidence rate of UC in China has increased year by year, but there is no effective cure method in Western medicine. Traditional Chinese medicine treatment based on syndrome differentiation has the unique advantages of simplicity, convenience, effectiveness, and low cost. Therefore, integration of Chinese and Western medicine has become an important strategy for UC diagnosis and treatment, and has made significant progress in UC. On the basis of learning from a number of consensuses at home and abroad, combined with Chinese research results and the actual clinical situation of traditional Chinese and Western medicine, the UC group of the Chinese Association of Integrative Medicine has formulated the expert consensus on the diagnosis and treatment of UC with integrated traditional Chinese and Western medicine. In this consensus, the pathogenesis, etiology and pathogenesis, diagnosis, integrated traditional Chinese and Western medicine treatment, and chronic disease management with integrated traditional Chinese and Western medicine for UC were recommended by experts. This article interprets the consensus from the perspective of nursing in order to provide reference basis for clinical nursing workers.

English Else
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Christopher Andrew Lamb,Nicholas A Kennedy,Tim Raine,Philip Anthony Hendy,Philip J Smith,Jimmy K Limdi,Bu’Hussain Hayee,Miranda C E Lomer,Gareth C Parkes,Christian Selinger,Kevin J Barrett,R Justin Davies,Cathy Bennett,Stuart Gittens,Malcolm G Dunlop,Omar Faiz,Aileen Fraser,Vikki Garrick,Paul D Johnston,Miles Parkes,Jeremy Sanderson,Helen Terry,Daniel R Gaya,Tariq H Iqbal,Stuart A Taylor,Melissa Smith,Matthew Brookes,Richard Hansen,A Barney Hawthorne,Ian Arnott,Kevin J Barrett,R Mark Beattie,Stuart Bloom,Keith Bodger,Richard R Brady,Matthew J Brookes,Steven R Brown,Jeffrey R Butterworth,Christopher R Calvert,Rachel Campbell,Tom Creed,Nicholas M Croft,Fraser Cummings,R Justin Davies,David Devadason,Anjan Dhar,Chris Dipper,Julie Duncan,Malcolm Dunlop,Dharmaraj Durai,Martyn D Evans,Omar Faiz,Nicola S Fearnhead,Alexander C Ford,Aileen Fraser,Vikki Garrick,Daniel R Gaya,James Goodhand,Nigel Hall,Richard Hansen,Marcus Harbord,A Barney Hawthorne,Bu’Hussain Hayee,Sarah Hearnshaw,Paul Henderson,Philip Hendy,Tariq Iqbal,Paul D Johnston,Nicholas A Kennedy,Christopher A Lamb,Jimmy K Limdi,James O Lindsay,Alan J Lobo,Miranda Lomer,Richard E Lovegrove,John C Mansfield,Simon Mclaughlin,Christopher G Mountford,Rafeeq Muhammed,Nurulamin M Noor,Simon Panter,Gareth C Parkes,Miles Parkes,Thomas D Pinkney,Chris Probert,Tim Raine,Richard K Russell,Matthew D Rutter,Mark A Samaan,Jeremy D Sanderson,Christian P Selinger,Ashit Shah,Steve J Short,Baljit Singh,Philip J Smith,Melissa Smith,R Alexander Speight,Catherine Stansfield,Helen Steed,Stuart A Taylor,Helen Terry,Tony C Tham,Nick P Thompson,Gareth J Walker,Catherine L Wall,Janindra Warusavitarne,Gethin L Williams,R Graeme Wilson,David C Wilson,Lisa C Younge,

DOI: https://doi.org/10.1136/gutjnl-2019-318484

IF: 24.5

2019-09-27

Gut

Abstract:Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn’s disease, including patients, their families and friends.

gastroenterology & hepatology
Initial treatment seeking from professional health care providers for eating disorders: A review and synthesis of potential barriers to and facilitators of “first contact”

P. Regan,F. Cachelin,Alyssa M Minnick

DOI: https://doi.org/10.1002/eat.22683

2017-03-01

International Journal of Eating Disorders

Abstract:The objective of this study is to provide a comprehensive review of empirical research exploring barriers to and facilitators of initial treatment seeking ("first contact") from professional health care providers by adults and young adults with eating disorders (EDs). A search of databases PsycINFO and MEDLINE using the terms "treatment" and "eating disorder*" yielded 9,468 peer-reviewed articles published from January 1945 to June 2016. Screening identified 31 articles meeting the following criteria: (1) participants were 16 or older and presented with a self-reported or clinically diagnosed ED; (2) studies focused on (a) initial treatment seeking (b) for an ED (c) from professional health care providers; (3) articles were empirical, and (4) peer reviewed. Quantitative studies revealed few consistent correlates of treatment seeking, perhaps because most variables were examined in only one or two investigations. Variables with some degree of predictive utility (i.e., produced significant results in multiple studies) were age (older), ethnicity (nonethnic minority), ED type (anorexia, purging BN), specific ED-related behaviors (i.e., purging), and time spent on a treatment waitlist following referral (less). Although BMI was one of the most investigated variables, it did not predict treatment seeking. Qualitative studies revealed the following perceived barriers: (1) personal feelings of shame/fear, (2) ED-related beliefs/perceptions, (3) lack of access/availability, and (4) aspects of the treatment process. Perceived facilitators included (1) health-related concerns, (2) emotional distress, and (3) social support. Implications for clinical practice and areas for further research are discussed. Results highlight the need for shared definitions and methodologies across studies of treatment seeking.
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia

Shu-Chen Wei,Jose Sollano,Yee Tak Hui,Wei Yu,Paul V. Santos Estrella,Lyndon John Q. Llamado,Nana Koram

DOI: https://doi.org/10.1080/17474124.2021.1840976

2021-01-19

Abstract:Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the colon, characterized by relapsing and remitting symptoms. Although traditionally viewed as a Western disease, the incidence and prevalence of UC is increasing in developing regions, including Asian countries.A PubMed search identified articles describing epidemiology, disease burden, patient demographics, clinical characteristics, risk factors, and treatment of UC across Asia. We review the epidemiology and disease course of UC across Asia, including region-specific factors that may aid development of more cost-effective treatment approaches tailored to the needs of Asian populations.The opinion of non-Pfizer-affiliated practicing gastroenterologists is that epidemiological data from the last four decades have shown 1.5-fold to almost 20-fold increases in the incidence and prevalence of UC in some Asian countries, although prevalence remains generally lower than in the West. As the prevalence of UC rises, so will overall healthcare costs. Disparities in healthcare systems and funding mean that different Asian countries face unique challenges in how best to use available resources, including selection from a growing number of emerging treatment options. More clinical trial and real-world data are required to help define treatment approaches that will most benefit Asian populations.

gastroenterology & hepatology
A comprehensive review and update on ulcerative colitis

Mahesh Gajendran,Priyadarshini Loganathan,Guillermo Jimenez,Anthony P Catinella,Nathaniel Ng,Chandraprakash Umapathy,Nathalie Ziade,Jana G Hashash

DOI: https://doi.org/10.1016/j.disamonth.2019.02.004

Abstract:Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disorder of the colon that causes continuous mucosal inflammation extending from the rectum to the more proximal colon, with variable extents. UC is characterized by a relapsing and remitting course. UC was first described by Samuel Wilks in 1859 and it is more common than Crohn's disease worldwide. The overall incidence and prevalence of UC is reported to be 1.2-20.3 and 7.6-245 cases per 100,000 persons/year respectively. UC has a bimodal age distribution with an incidence peak in the 2nd or 3rd decades and followed by second peak between 50 and 80 years of age. The key risk factors for UC include genetics, environmental factors, autoimmunity and gut microbiota. The classic presentation of UC include bloody diarrhea with or without mucus, rectal urgency, tenesmus, and variable degrees of abdominal pain that is often relieved by defecation. UC is diagnosed based on the combination of clinical presentation, endoscopic findings, histology, and the absence of alternative diagnoses. In addition to confirming the diagnosis of UC, it is also important to define the extent and severity of inflammation, which aids in the selection of appropriate treatment and for predicting the patient's prognosis. Ileocolonoscopy with biopsy is the only way to make a definitive diagnosis of UC. A pathognomonic finding of UC is the presence of continuous colonic inflammation characterized by erythema, loss of normal vascular pattern, granularity, erosions, friability, bleeding, and ulcerations, with distinct demarcation between inflamed and non-inflamed bowel. Histopathology is the definitive tool in diagnosing UC, assessing the disease severity and identifying intraepithelial neoplasia (dysplasia) or cancer. The classical histological changes in UC include decreased crypt density, crypt architectural distortion, irregular mucosal surface and heavy diffuse transmucosal inflammation, in the absence of genuine granulomas. Abdominal computed tomographic (CT) scanning is the preferred initial radiographic imaging study in UC patients with acute abdominal symptoms. The hallmark CT finding of UC is mural thickening with a mean wall thickness of 8 mm, as opposed to a 2-3 mm mean wall thickness of the normal colon. The Mayo scoring system is a commonly used index to assess disease severity and monitor patients during therapy. The goals of treatment in UC are three fold-improve quality of life, achieve steroid free remission and minimize the risk of cancer. The choice of treatment depends on disease extent, severity and the course of the disease. For proctitis, topical 5-aminosalicylic acid (5-ASA) drugs are used as the first line agents. UC patients with more extensive or severe disease should be treated with a combination of oral and topical 5-ASA drugs +/- corticosteroids to induce remission. Patients with severe UC need to be hospitalized for treatment. The options in these patients include intravenous steroids and if refractory, calcineurin inhibitors (cyclosporine, tacrolimus) or tumor necrosis factor-α antibodies (infliximab) are utilized. Once remission is induced, patients are then continued on appropriate medications to maintain remission. Indications for emergency surgery include refractory toxic megacolon, colonic perforation, or severe colorectal bleeding.
ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin,Ashwin N. Ananthakrishnan,Corey A. Siegel,Bryan G. Sauer,Millie D. Long

DOI: https://doi.org/10.14309/ajg.0000000000000152

2019-02-27

Abstract:Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. In instances where the evidence was not appropriate for GRADE, but there was consensus of significant clinical merit, "key concept" statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not only, approach to clinical scenarios.

gastroenterology & hepatology
The Mechanism and Progress of Traditional Chinese Medicine in Treating Ulcerative Colitis

Li Yan,Chen Rui

DOI: https://doi.org/10.62022/ricm.issn3005-5482.2024.02.004

2024-12-20

Abstract:Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the rectum and colon with unclear etiology, characterized by abdominal pain, diarrhea, and mucopurulent bloody stools. The majority of lesions in this disease involve the mucosa and submucosa of the rectum and sigmoid colon, which can extend to the distal end and even spread throughout the entire colon. The severity of this disease varies, and it often presents a chronic course of recurrent attacks. It is difficult to cure and has the possibility of cancer transformation. It has been listed as one of the modern difficult to treat diseases by the WHO. The incidence rate and prevalence of the disease have obvious regional and ethnic differences, with North American and Nordic whites the highest. However, in recent decades, the incidence rate of the disease in China has continued to increase. Traditional Chinese medicine has certain advantages in treating UC, and its therapeutic effect is not inferior to that of Western medicine. It has fewer adverse reactions and lower costs, and has good social and economic significance. This article provides an overview of the mechanism and clinical research status of traditional Chinese medicine in treating UC, in order to provide more ideas for the treatment research of this disease.
[Headache and impacted upper wisdom teeth].

M. Romoli,G. Cudia

Revue de Stomatologie et de Chirurgie Maxillo-faciale

Abstract:The relationships between wisdom tooth and headache have been rarely studied. The aim of this paper was to follow 13 patients, which suffered with idiopathic headache, after extraction of impacted maxillary wisdom tooth. The authors separated in two group the patients on the basis of a different anatomic site of pain. Patients with bilateral headache or monolateral headache without preferable anatomic site did not respond positively to the extractions. On the other hand the group of patients with monolateral headache or bilateral headache with preferable anatomic site obtained an improvement after the extraction of the maxillary homolateral wisdom tooth.
Management of ulcerative colitis: where are we at and where are we heading?

Adnan Abbas,David M. P. Di Fonzo,Panu Wetwittayakhlang,Reem Al-Jabri,Peter L. Lakatos,Talat Bessissow

DOI: https://doi.org/10.1080/17474124.2024.2422370

2024-11-09

Expert Review of Gastroenterology & Hepatology

Abstract:Introduction Remission rates for ulcerative colitis (UC) remain low despite significant progress in disease understanding and the introduction of novel therapeutic agents. Several challenges contribute to this, including the heterogeneity of the disease, suboptimal efficacy of current diagnostic and therapeutic tools, drug safety concerns, and limited access to newer treatment options.

gastroenterology & hepatology
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Yu-Yun Shao,Shen-Yung Wang,Shi-Ming Lin,Diagnosis Group,Kuan-Yang Chen,Jeng-Hwei Tseng,Ming-Chih Ho,Rheun-Chuan Lee,Po-Chin Liang,Li-Ying Liao,Kai-Wen Huang,Jui-Ting Hu,Ja-Der Liang,Shen-Yung Wang,Kwong-Ming Kee,Chih-Lin Lin,Systemic Therapy Group,Shi-Ming Lin,Chung-Kwe Wang,Sheng-Nan Lu,Jing-Houng Wang,Wei-Chen Lee,Chien-Hung Chen,Chun-Jen Liu,Yi-Hsiang Huang,Chia-Chi Wang,Tsang-En Wang,Po-Heng Chuang,Chia-Yen Dai,Chiun Hsu,Yu-Yun Shao,San-Chi Chen,Chia-Hsun Hsieh

DOI: https://doi.org/10.1016/j.jfma.2020.10.031

IF: 3.871

2021-04-01

Journal of the Formosan Medical Association

Abstract:<p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.</p>

medicine, general & internal
Ulcerative colitis: molecular insights and intervention therapy

Yuqing Liang,Yang Li,Chehao Lee,Ziwei Yu,Chongli Chen,Chao Liang

DOI: https://doi.org/10.1186/s43556-024-00207-w

2024-10-10

Abstract:Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, diarrhea, rectal bleeding, and weight loss. The pathogenesis and treatment of UC remain key areas of research interest. Various factors, including genetic predisposition, immune dysregulation, and alterations in the gut microbiota, are believed to contribute to the pathogenesis of UC. Current treatments for UC include 5-aminosalicylic acids, corticosteroids, immunosuppressants, and biologics. However, study reported that the one-year clinical remission rate is only around 40%. It is necessary to prompt the exploration of new treatment modalities. Biologic therapies, such as anti-TNF-α monoclonal antibody and JAK inhibitor, primarily consist of small molecules targeting specific pathways, effectively inducing and maintaining remission. Given the significant role of the gut microbiota, research into intestinal microecologics, such as probiotics and prebiotics, and fecal microbiota transplantation (FMT) shows promising potential in UC treatment. Additionally, medicinal herbs, such as chili pepper and turmeric, used in complementary therapy have shown promising results in UC management. This article reviews recent findings on the mechanisms of UC, including genetic susceptibility, immune cell dynamics and cytokine regulation, and gut microbiota alterations. It also discusses current applications of biologic therapy, herbal therapy, microecologics, and FMT, along with their prospects and challenges.
Ulcerative colitis

Taku Kobayashi,Britta Siegmund,Catherine Le Berre,Shu Chen Wei,Marc Ferrante,Bo Shen,Charles N. Bernstein,Silvio Danese,Laurent Peyrin-Biroulet,Toshifumi Hibi

DOI: https://doi.org/10.1038/s41572-020-0205-x

IF: 81.5

2020-09-10

Nature Reviews Disease Primers

Abstract:Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis. UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries. An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments. Since the early 2000s, anti-tumour necrosis factor (TNF) treatment has significantly improved treatment outcomes. Advances in medical treatments have enabled a paradigm shift in treatment goals from symptomatic relief to endoscopic and histological healing to achieve better long-term outcomes and, consequently, diagnostic modalities have also been improved to monitor disease activity more tightly. Despite these improvements in patient care, a substantial proportion of patients, for example, those who are refractory to medical treatment or those who develop colitis-associated colorectal dysplasia or cancer, still require restorative proctocolectomy. The development of novel drugs and improvement of the treatment strategy by implementing personalized medicine are warranted to achieve optimal disease control. However, delineating the aetiology of UC is necessary to ultimately achieve disease cure.

medicine, general & internal
Global trends and hotspots of ulcerative colitis based on bibliometric and visual analysis from 1993 to 2022

Jing Wang,Tangyou Mao,Hengyu Zhou,Xinqi Jiang,Zhihui Zhao,Xiaoqing Zhang

DOI: https://doi.org/10.1097/md.0000000000037095

IF: 1.6

2024-02-03

Medicine

Abstract:Ulcerative colitis (UC) is a chronic inflammatory bowel disease that exhibits nonspecific characteristics, involving inflammation limited to the colon mucosa and submucosa, explicitly impacting the rectum and sigmoid colon. Clinical symptoms include persistent or recurrent abdominal pain, diarrhea, mucus, and bloody stools. It is difficult to treat and has a long duration. Severe cases can lead to local or systemic complications and an increased risk of developing cancer. [ 1 , 2 ] The disease is recognized as a difficult-to-treat inflammatory bowel disease by the World Health Organization. Although the incidence of UC is high in Europe and North America, it is stable, while in Asia and the Middle East, the incidence is low but has been reported to be on the rise in recent years. [ 3 , 4 ] Till now, the exact etiology and pathogenesis of UC are still not comprehensively understood. It is thought to arise from a complex interplay of various factors, including genetic predisposition, environmental influences, infectious agents, psychological factors, and dysfunction in the mucosal immune system. [ 5 ] Current clinical treatment for UC primarily utilizes anti-inflammatory drugs, including 5-aminosalicylic acid, corticosteroids, immunosuppressants, and biological agents. However, these drugs can cause adverse reactions, opportunistic infections, bone marrow suppression and tumor induction. [ 6 , 7 ] Emerging therapies such as bone marrow stem cell transplantation and fecal microbiota transplantation (FMT) are still in the early stages of development. These costly treatments have unpredictable efficacy, significantly burdening individuals, families, and society. [ 8 , 9 ] The rising prevalence of UC and the absence of safe and effective treatments underscore the significance of UC research as a cutting-edge frontier in scientific investigation.

medicine, general & internal
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment

Hong-Hwa Chen,Tao-Wei Ke,Ching-Wen Huang,Jeng-Kae Jiang,Chou-Chen Chen,Yao-Yu Hsieh,Hao-Wei Teng,Bo-Wen Lin,Yi-Hsin Liang,Yu-Li Su,Hung-Chih Hsu,Feng-Che Kuan,Yenn-Hwei Chou,Johnson Lin,Ben-Ren Lin,Yu-Yao Chang,Jaw-Yuan Wang

DOI: https://doi.org/10.3389/fonc.2021.764912

IF: 4.7

2021-11-15

Frontiers in Oncology

Abstract:Therapeutic options for metastatic CRC (mCRC) have changed significantly in recent years, greatly increasing the complexity of therapeutic decision-making. Although oncology guidelines have helped improve the care process, guidelines may also limit the flexibility to individualize in-clinic decision-making. This consensus paper addresses specific gaps in the current international guidelines to assist Taiwanese colon and rectal experts make specific therapeutic choices. Over 3 years and three meetings with selected experts on “real-world” Taiwanese practice patterns for mCRC, consensus was achieved. The experts also discussed specific questions during in-depth one-on-one consultation. Outcomes of the discussion were then correlated with published evidence by an independent medical writer. The final consensus includes clinically implementable recommendations to provide guidance in treating Taiwanese mCRC patients. The consensus includes criteria for defining fit and unfit intensive treatment patients, treatment goals, treatment considerations of molecular profiles, treatment consideration, and optimal treatment choices between different patient archetypes, including optimal treatment options based on RAS , BRAF , and microsatellite instability (MSI) status. This consensus paper is the second in the Taiwan Society of Colon and Rectal Surgeons (TSCRS) Consensus series to address unmet gaps in guideline recommendations in lieu of Taiwanese mCRC management. Meticulous discussions with experts, the multidisciplinary nature of the working group, and the final drafting of the consensus by independent medical professionals have contributed to the strong scientific value of this consensus.

oncology
Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis

Wei-Dar Chen,Cheng-Hsiu Wu,Po-Yi Wu,Chang-Ping Lin,Liang-Shiou Ou,De-Kuang Hwang,Shwu-Jiuan Sheu,Wei-Yu Chiang,Yo-Chen Chang,Chun-Ju Lin,Wei-Chun Chan,Yueh-Fu Fang,Jerry Chien-Chieh Huang,Tzu-En Kao,Fang-Yi Chiu,Ning-Yi Hsia,Yih-Shiou Hwang

DOI: https://doi.org/10.1016/j.jfma.2024.02.010

IF: 3.871

2024-02-01

Journal of the Formosan Medical Association

Abstract:We presented the development of a consensus guideline for managing juvenile idiopathic arthritis-associated uveitis (JIAU) in Taiwan, considering regional differences in manifestation and epidemiology. The Taiwan Ocular Inflammation Society (TOIS) committee formulated this guideline using a modified Delphi approach with two panel meetings. Recommendations were based on a comprehensive evidence-based literature review and expert clinical experiences, and were graded according to the Oxford Centre for Evidence-Based Medicine's "Levels of Evidence" guideline (March 2009). The TOIS consensus guideline consists of 10 recommendations in four categories: screening and diagnosis, treatment, complications, and monitoring, covering a total of 27 items. These recommendations received over 75% agreement from the panelists. Early diagnosis and a coordinated referral system between ophthalmologists and pediatric rheumatologists are crucial to prevent irreversible visual impairment in children with JIAU. However, achieving a balance between disease activity and medication use remains a key challenge in JIAU management, necessitating further clinical studies.

medicine, general & internal
Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements

Alain Bitton,Donald Buie,Robert Enns,Brian G Feagan,Jennifer L Jones,John K Marshall,Scott Whittaker,Anne M Griffiths,Remo Panaccione

DOI: https://doi.org/10.1038/ajg.2011.386

2012-02-01

Abstract:OBJECTIVES: The objective of this study was to provide updated explicit and relevant consensus statements for clinicians to refer to when managing hospitalized adult patients with acute severe ulcerative colitis (UC).METHODS: The Canadian Association of Gastroenterology consensus group of 23 voting participants developed a series of recommendation statements that addressed pertinent clinical questions. An iterative voting and feedback process was used to do this in conjunction with systematic literature reviews. These statements were brought to a formal consensus meeting held in Toronto, Ontario (March 2010), when each statement was discussed, reformulated, voted upon, and subsequently revised until group consensus (at least 80% agreement) was obtained. The modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria were used to rate the strength of recommendations and the quality of evidence.RESULTS: As a result of the iterative process, consensus was reached on 21 statements addressing four themes (General considerations and nutritional issues, Steroid use and predictors of steroid failure, Cyclosporine and infliximab, and Surgical issues).CONCLUSIONS: Key recommendations for the treatment of hospitalized patients with severe UC include early escalation to second-line medical therapy with either infliximab or cyclosporine in individuals in whom parenteral steroids have failed after 72 h. These agents should be used in experienced centers where appropriate support is available. Sequential therapy with cyclosporine and infliximab is not recommended. Surgery is an option when first-line steroid therapy fails, and is indicated when second-line medical therapy fails and/or when complications arise during the hospitalization.

gastroenterology & hepatology
An Overview of Emerging Trends and Technologies in Ulcerative Colitis

Ari Mendell,Kim Le,Chris Vannabouathong,Quenby Mahood

DOI: https://doi.org/10.51731/cjht.2023.696

2023-07-19

Canadian Journal of Health Technologies

Abstract:This report provides an overview of the evolving therapeutic landscape for moderate to severe ulcerative colitis (UC), including recent changes to clinical practice guidelines, key trends in therapeutic strategies, and new or emerging treatment options, with a focus on biologics and small-molecule therapies. Recent guidelines on the medical management of patients with UC include those of the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), and European Crohn’s and Colitis Organisation (ECCO), which were published in 2019, 2020, and 2022, respectively. These guidelines provide an accurate reflection of how clinical practice has changed to incorporate newer therapies that have entered the market and newer evidence that has been published since the release of the Canadian guidelines in 2015. The ACG, AGA, and ECCO guidelines all recommend use of a tumour necrosis factor (TNF) antagonist, vedolizumab, or tofacitinib for induction of remission in patients with moderate to severe UC; the AGA and ECCO guidelines also recommend ustekinumab as an option and recommend vedolizumab over adalimumab, whereas the AGA guidelines recommend early use of biologic drugs over a step-up approach after failure of 5-aminosalicylates. Two important trends in therapeutic strategies for UC include changes in the use and definition of treatment targets and recommendations regarding therapeutic drug monitoring (TDM). The 2021 Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) guidelines provide contemporary consensus recommendations for using new and updated targets throughout an individualized treatment timeline in patients with inflammatory bowel disease (IBD). Although histologic remission is not considered a formal UC treatment target in STRIDE-II, it is acknowledged as an adjunctive measure to endoscopic remission to represent a deeper level of healing and is the focus of many current studies. The use of TDM emerged from challenges associated with the use of older biologics (primarily TNF antagonists), which posed difficulties related to immunogenicity and dosing. The relevance of TDM for newer biologics with different mechanisms of action, reduced immunogenicity, and fixed dosing (e.g., vedolizumab and ustekinumab) is a topic of ongoing debate. Although AGA guidelines on TDM in IBD and expert consensus statements support the use of reactive TDM for patients with UC who lose response to a TNF antagonist, evidence gaps remain regarding appropriate use of proactive TDM, utility of TDM for small molecules and biologics outside of the TNF antagonist class, and consistent target concentration thresholds to guide dose changes. There is a substantial pipeline of new and emerging drugs for the treatment of adults with moderate to severe UC, with many in phase IIb or III of clinical development; several notable trends of emerging pharmacotherapies exist, including an increasing number of Janus kinase inhibitors, several therapies with biologic targets that are new in UC (e.g., interleukin-23 antibodies, TNF-like ligand 1A inhibitors), an increasing number of oral therapies, and the first combination of 2 biologic therapies in UC. The Canadian health care system should be prepared to adapt to the rapidly evolving treatment landscape and potential clinical practice changes in moderate to severe UC. Drugs with new mechanisms of action in the treatment area and the new paradigm of combination therapy with multiple biologics of different classes may lead to improved patient outcomes but can also further complicate the treatment decision-making process. Therefore, it is important for health care providers to stay up to date on new and upcoming treatment options, which may require educational initiatives for both providers and patients as well as updates to the Canadian treatment guidelines. Overall, potential changes on the horizon may have substantial implications for the health care system given the prevalence of UC in Canada, the costs of advanced therapies, and the increasing number of available treatment options.

Demonstration of vitamin D3 metabolism inmytilus edulis

International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023)

On the validity of continuous spectrophotometric assays for adenosine deaminase activity: a critical reappraisal.

Update of the PANCCO clinical practice guidelines for the treatment of ulcerative colitis in the adult population

Expert consensus on diagnosis and treatment of ulcerative colitis with integrated traditional Chinese and Western medicine: A nursing perspective

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Initial treatment seeking from professional health care providers for eating disorders: A review and synthesis of potential barriers to and facilitators of “first contact”

Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia

A comprehensive review and update on ulcerative colitis

ACG Clinical Guideline: Ulcerative Colitis in Adults

The Mechanism and Progress of Traditional Chinese Medicine in Treating Ulcerative Colitis

[Headache and impacted upper wisdom teeth].

Management of ulcerative colitis: where are we at and where are we heading?

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Ulcerative colitis: molecular insights and intervention therapy

Ulcerative colitis

Global trends and hotspots of ulcerative colitis based on bibliometric and visual analysis from 1993 to 2022

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment

Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis

Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements

An Overview of Emerging Trends and Technologies in Ulcerative Colitis